Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Immune Checkpoint Inhibitor–Based Therapy for Early-Stage Lung Cancer: Surgeon Perspective
  • CME
  • CE

person default
Jonathan Spicer, MD, PhD, FRCS
Released: December 1, 2021
Back Next

References

  1. Asamura H, Okada M, Saji H, et al. Randomized trial of segmentectomy compared to lobectomy in small-sized peripheral non-small cell lung cancer (JCOG0802/WJOG4607L). Presented at: 101st Annual Meeting of the American Association of Thoracic Surgery. April 30-May 2, 2021.
  2. Wu Y, Tsuboi M, He J, et al. Osimertinib in resected EGFR-mutated non-small-cell lung cancer. N Engl J Med. 2020;383:1711-1723.
  3. Felip E, Altorki N, Zhou C, et al. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (Impower010): a randomised, multicentre, open-label, phase 3 trial. Lancet. 2021;398:1344-1357.
  4. Albain KS, Swann RS, Rusch VW, et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet. 2009;374:379-386.
  5. Hui Z, Men Y, Hu C, et al. Effect of postoperative radiotherapy for patients with pIIIA-N2 non-small-cell lung cancer after complete resection and adjuvant chemotherapy: the phase32 PORT-C randomized clinical trial. JAMA Oncol. 2021;7:1178.
  6. Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med. 2017;377:1919-1929.
  7. Antonia SJ, Villegas A, Daniel D, et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med. 2018;379:2342-2350.
  8. Roth JA, Fossella F, Komaki R, et al. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. J Natl Cancer Inst. 1994;86:673-680.
  9. Rosell R, Gómez-Codina J, Camps, C, et al. A randomized trial comparing perioperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med. 1994;330:153-158.
  10. Goldstraw P, Chansky K, Crowley J, et al. The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J Thorac Oncol. 2016;11:39-51.
  11. Forde PM, Chaft JE, Smith KN, et al. Neoadjuvant PD-1 blockade in resectable lung cancer. N Engl J Med. 2018;378:1976.
  12. Huynh C, Walsh LA, Spicer JD. Surgery after neoadjuvant immunotherapy in patients with resectable non-small cell lung cancer. Transl Lung Cancer Res. 2021;10:563-580.
  13. Hellmann MD, Chaft JE, William WB Jr, et al. Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint. Lancet Oncol. 2014;15:e42-50.
  14. Ferreira V, Minnella EM, Awasthi R, et al. Multimodal prehabilitation for lung cancer surgery: a randomized controlled trial. Ann Thorac Surg. 2021;112:1600-1608.
  15. Schmid S, Minnella EM, Najmeh S, et al. Neoadjuvant prehabilitation therapy for locally advanced non-small-cell lung cancer: optimizing outcomes through the trajectory of care. Presented at: 57th Annual Meeting of the American Society of Clinical Oncology Meeting; June 4-8, 2021. Abstract e20545.
  16. Brandt WS, Yan W, Zhou J, et al. Outcomes after neoadjuvant or adjuvant chemotherapy for cT2-4N0-1 non-small cell lung cancer: a propensity-matched analysis. J Thorac Cardiovasc Surg. 2019;157:743-753.
  17. ClinicalTrials.gov. A study of atezolizumab as neoadjuvant and adjuvant therapy in resectable non-small cell lung cancer (NSCLC) – Lung cancer mutation consortium (LCMC3). clinicaltrials.gov/ct2/show/NCT02927301. Accessed November 16, 2021.
  18. Lee JM, Chaft J, Nicholas A, et al: Surgical and clinical outcomes with neoadjuvant atezolizumab in resectable stage IB–IIIB NSCLC: LCMC3 trial primary analysis. Presented at: 22nd World Conference On Lung Cancer of the International Association for the Study of Lung Cancer; January 28-31, 2021. Abstract PS02.05.
  19. Shu CA, Gainor JF, Awad MM, et al. Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol. 2020;21:786-795.
  20. Provencio M, Nadal E, Insa A, et al. Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol. 2020;21:1413-1422.
  21. Forde PM, Spicer J, Lu S, et al. Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo as neoadjuvant treatment (tx) for resectable (IB-IIIA) non-small cell lung cancer (NSCLC) in the phase 3 checkmate 816 trial. Presented at: American Association for Cancer Research Annual Meeting 2021; April 10-15, 2021. Abstract CT003.
  22. Spicer J, Wang C, Tanaka F, et al. Surgical outcomes from the phase 3 checkMate 816 trial: nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo alone as neoadjuvant treatment for patients with resectable non-small cell lung cancer (NSCLC). Presented at: 57th Annual Meeting of the American Society of Clinical Oncology Meeting; June 4-8, 2021. Abstract 8503.
  23. ClinicalTrials.gov. A neoadjuvant study of nivolumab plus ipilimumab or nivolumab plus chemotherapy versus chemotherapy alone in early stage non-small cell lung cancer (NSCLC) (checkmate 816). clinicaltrials.gov/ct2/show/NCT02998528. Accessed November 16, 2021.
  24. Lim EK, Batchelor TJ, Dunning J, et al. Video-assisted thoracoscopic versus open lobectomy in patients with early-stage lung cancer: one-year results from a randomized controlled trial (VIOLET). Presented at: 57th Annual Meeting of the American Society of Clinical Oncology Meeting. June 4-8, 2021. Abstract 8504.
  25. Yoshino I, Yokoyama H, Yano T. Comparison of surgical results of lobectomy with bronchoplasty and pneumonectomy for lung cancer. J Surg Oncol. 1997;64:32-35.
  26. Frick AE, Lüders H, Leschber G. Thirty and 90-day mortality after lung cancer resection in 2242 patients. Presented at: 2015 European Lung Cancer Conference. April 15-18, 2015. Abstract 620.
  27. Blumenthal GM, Bunn PA Jr, Chaft JE, et al. Current status and future perspectives on neoadjuvant therapy in lung cancer. J Thorac Oncol. 2018;13:1818-1831.
  28. ClinicalTrials.gov. LCRF LEADER neoadjuvant screening trial: LCMC4 evaluation of actionable drivers in early stage lung cancers. https://www.clinicaltrials.gov/ct2/show/NCT04712877. Accessed November 16, 2021.
  29. Osimertinib [prescribing Information]. Wilmington, DE: AstraZeneca Pharmaceuticals; 2021.
  30. Atezolizumab [prescribing information]. South San Francisco, CA: Genentech; 2021.
  31. Alectinib [prescribing information]. South San Francisco, CA: Genentech; 2021.
  32. ClinicalTrials.gov. Pembrolizumab as neoadjuvant therapy for resectable stage IA3 to IIA non-small cell lung cancer (NSCLC). clinicaltrials.gov/ct2/show/NCT04638582. Accessed November 16, 2021.
Back Next

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings